Association of functional polymorphisms in CYP19A1 with aromatase inhibitor associated arthralgia in breast cancer survivors

Table 1 Demographic characteristics of participants

	N	%
Total (N, %)	390	81.9
Age, years (Mean, SD)	61.6	9.88
Educational Level (N, %)
High school or less	69	17.7
College or more	321	82.3
Reasons for menopause (N, %)
Natural	206	55.7
Induced	164	44.3
Years since LMP (N, %)
<5	76	19.8
5 to 10	104	27.1
>10	204	53.1
Body mass index, kg/m2 (Mean, SD)	26.7	5.6
Stage (N, %)
0 and I	149	38.2
II	200	51.3
III	41	10.5
Chemotherapy (N, %)
None	143	36.7
Chemotherapy, but no Taxane	97	24.9
Chemotherapy included Taxane	150	38.5
Currently on AIs	355	91
Aromatase inhibitors ¹
Letrozole (Femara)	71	20.0
Anastrozole (Arimidex)	241	67.9
Exemestane (Aromasin)	43	12.1
Years since start of AI ¹
<1	114	31.9
1 to 3	111	31.1
>3	132	37.0

Abbreviations: AIs, aromatase inhibitors; LMP, last menstrual period; SD, standard deviation.
¹Among those who are currently on AIs.
Not all cells add up due to missing variables.

ISSN: 1465-542X